Generics in Japan

Executive Summary

Market value

Market value forecast

Market volume

Market volume forecast

Geography segmentation

Market rivalry

Market Overview

Market definition

Market analysis

Market Data

Market value

Market volume

Market Segmentation

Geography segmentation

Market Outlook

Market value forecast

Market volume forecast

Five Forces Analysis

Summary

Buyer power

Supplier power

New entrants

Threat of substitutes

Degree of rivalry

Leading Companies

Daiichi Sankyo Co., Ltd.

Sawai Pharmaceutical Co., Ltd.

Teva Pharmaceutical Industries Limited

Macroeconomic Indicators

Country data

Methodology

Industry associations

Related MarketLine research

Appendix

About MarketLine

List of Tables

Table 1: Japan generics market value: $ billion, 2012–16(e)

Table 2: Japan generics market volume: % of total pharma volume, 2012–16(e)

Table 3: Japan generics market geography segmentation: $ billion, 2016(e)

Table 4: Japan generics market value forecast: $ billion, 2016–21

Table 5: Japan generics market volume forecast: % of total pharma volume, 2016–21

Table 6: Daiichi Sankyo Co., Ltd.: key facts

Table 7: Daiichi Sankyo Co., Ltd.: key financials ($)

Table 8: Daiichi Sankyo Co., Ltd.: key financials (¥)

Table 9: Daiichi Sankyo Co., Ltd.: key financial ratios

Table 10: Sawai Pharmaceutical Co., Ltd.: key facts

Table 11: Sawai Pharmaceutical Co., Ltd.: key financials ($)

Table 12: Sawai Pharmaceutical Co., Ltd.: key financials (¥)

Table 13: Sawai Pharmaceutical Co., Ltd.: key financial ratios

Table 14: Teva Pharmaceutical Industries Limited: key facts

Table 15: Teva Pharmaceutical Industries Limited: key financials ($)

Table 16: Teva Pharmaceutical Industries Limited: key financial ratios

Table 17: Japan size of population (million), 2012–16

Table 18: Japan gdp (constant 2005 prices, $ billion), 2012–16

Table 19: Japan gdp (current prices, $ billion), 2012–16

Table 20: Japan inflation, 2012–16

Table 21: Japan consumer price index (absolute), 2012–16

Table 22: Japan exchange rate, 2012–16

List Of Figures

Figure 1: Japan generics market value: $ billion, 2012–16(e)

Figure 2: Japan generics market volume: % of total pharma volume, 2012–16(e)

Figure 3: Japan generics market geography segmentation: % share, by value, 2016(e)

Figure 4: Japan generics market value forecast: $ billion, 2016–21

Figure 5: Japan generics market volume forecast: % of total pharma volume, 2016–21

Figure 6: Forces driving competition in the generics market in Japan, 2016

Figure 7: Drivers of buyer power in the generics market in Japan, 2016

Figure 8: Drivers of supplier power in the generics market in Japan, 2016

Figure 9: Factors influencing the likelihood of new entrants in the generics market in Japan, 2016

Figure 10: Factors influencing the threat of substitutes in the generics market in Japan, 2016

Figure 11: Drivers of degree of rivalry in the generics market in Japan, 2016

Figure 12: Daiichi Sankyo Co., Ltd.: revenues & profitability

Figure 13: Daiichi Sankyo Co., Ltd.: assets & liabilities

Figure 14: Sawai Pharmaceutical Co., Ltd.: revenues & profitability

Figure 15: Sawai Pharmaceutical Co., Ltd.: assets & liabilities

Figure 16: Teva Pharmaceutical Industries Limited: revenues & profitability

Figure 17: Teva Pharmaceutical Industries Limited: assets & liabilities

Generics in Japan

Summary

Generics in Japan industry profile provides top-line qualitative and quantitative summary information including: market size (value and volume 2012-16, and forecast to 2021). The profile also contains descriptions of the leading players including key financial metrics and analysis of competitive pressures within the market.

Essential resource for top-line data and analysis covering the Japan generics market. Includes market size data, textual and graphical analysis of market growth trends, leading companies and macroeconomic information.

For the purposes of this profile, a generic is defined as a copy of an ethical (prescription) drug formerly protected by patents that have now expired. Both unbranded generics and all branded generics are included. However, off-patent drugs that continue to be offered by the original manufacturer under the original name, and which form part of the 'generic-eligible' market, are not included.

The Japanese generics market is expected to generate total revenues of $48.7bn in 2016, representing a compound annual growth rate (CAGR) of 18.8% between 2012 and 2016.

Market consumption volume is forecast to increase with a CAGR of 13.5% between 2012 and 2016, to reach a total of 42.8% of total pharma volume in 2016.

The Japanese generic market is something of a priority for the Japanese government. Unlike its G8 peers, generic market share in Japan is rather low. Due to an aging population and rising costs of branded drugs, healthcare policies to cut expenditure on medical costs have been implemented. These policies aim to increase generic market share to 80% of volume between 2018 and 2020.

Scope

• Save time carrying out entry-level research by identifying the size, growth, and leading players in the generics market in Japan
• Use the Five Forces analysis to determine the competitive intensity and therefore attractiveness of the generics market in Japan
• Leading company profiles reveal details of key generics market players’ global operations and financial performance
• Add weight to presentations and pitches by understanding the future growth prospects of the Japan generics market with five year forecasts by both value and volume

• What was the size of the Japan generics market by value in 2016?
• What will be the size of the Japan generics market in 2021?
• What factors are affecting the strength of competition in the Japan generics market?
• How has the market performed over the last five years?
• How large is Japan’s generics market in relation to its regional counterparts?